A publication involving degarelix was released on May 20, 2026. The article, titled "Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature," appeared in Cancer Chemotherapy and Pharmacology.
The publication is described as a case report combined with a review of literature. No findings, outcomes, or conclusions from the article have been provided beyond its title and journal placement.
Degarelix remains an approved compound. This publication is noted here strictly as a new entry in the literature and does not represent new regulatory action or a change in approval status.
Readers interested in additional context on degarelix, including its approved uses and regulatory background, can consult the compound overview.